PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) —
Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.
What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.
If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.
The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.
Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.
What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #AARD $AARD #Aardvark
Coastal Financial Corporation (NASDAQ: CCB):
Grabar Law Office is investigating claims on behalf of shareholders of Coastal Financial Corporation (NASDAQ: CCB).
What is This Investigation About? This investigation concerns possible breaches of fiduciary duties and other alleged misconduct by certain officers and directors of the Company.
Current Coastal Financial Corporation (NASDAQ: CCB) shareholders who have held Coastal shares since prior to October 28, 2024, are encouraged visit https://grabarlaw.com/the-latest/coastal-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.
What is Alleged? A recently filed federal securities fraud class action alleges that Coastal Financial Corporation (NASDAQ: CCB), through certain of its current and former executives, made materially false and misleading statements concerning the growth and credit quality of Coastal’s CCBX business, the adequacy of the Company’s risk-management and credit-monitoring practices, and the credit protections provided by CCBX partner indemnification agreements. Specifically, that complaint alleges that, while Coastal represented that CCBX growth was being pursued in a disciplined manner with an emphasis on credit quality and risk management, defendants failed to disclose that: 1) the credit quality of a substantial CCBX partner loan portfolio consisting of approximately $500 million in loans, or nearly 23% of all CCBX loans, had materially deteriorated; 2) the deterioration exposed Coastal to significant credit losses despite representations concerning the protections provided by CCBX partner indemnification agreements; and 3) Coastal’s risk-management and credit-monitoring practices were allegedly inadequate to identify, properly account for and mitigate the deterioration and resulting risks.
The truth was revealed when, on July 30, 2026, Coastal announced its second-quarter 2026 financial results and reported a surprise GAAP net loss of $42.1 million, driven primarily by a $68.8 million credit expense associated with a single CCBX partner relationship. Coastal also disclosed that the affected portfolio consisted of approximately $500 million in underlying loans, together with the related reimbursement exposure. The complaint additionally alleges that Chief Executive Officer Eric M. Sprink sold approximately $12 million of Coastal common stock during the Class Period, while former CFO Joel Edwards sold approximately $3.8 million. It is alleged that those sales occurred before the deterioration of the CCBX partner portfolio and Coastal’s resulting exposure were disclosed to investors.
What Can You Do Now? If you have owned Coastal Financial Corporation (NASDAQ: CCB) shares since prior to October 28, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/coastal-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #CoastalFinancial #CCB $CCB
Erasca, Inc. (NASDAQ: ERAS):
Grabar Law Office is investigating whether certain officers and directors of Erasca, Inc. (NASDAQ: ERAS) breached their fiduciary duties owed to the Company and its shareholders.
What is This Investigation About? The investigation concerns whether Erasca’s directors and senior executives maintained appropriate oversight, disclosure controls, compliance procedures, and risk-management systems relating to the Company’s public statements concerning ERAS-0015, a pan-RAS molecular glue candidate being developed for the treatment of RAS-mutant solid tumors.
If you are a current Erasca (NASDAQ: ERAS) shareholder who has held shares since prior to January 14, 2025, you seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085.
What is Alleged? According to a recently filed federal securities class action Erasca, Inc. (NASDAQ: ERAS), through certain of its officers, made materially misleading statements and omissions concerning ERAS-0015. Among other things, the underlying class action complaint alleges that: Erasca publicly promoted ERAS-0015 as a potential “best-in-class” therapy and made repeated comparisons between ERAS-0015 and Revolution Medicines’ RMC-6236; the Company’s public disclosures allegedly relied upon improper comparisons to RMC-6236; Erasca allegedly faced intellectual property, patent, and trade-secret-related risks associated with those comparisons and related disclosures; investors allegedly were not adequately informed of those risks; and certain positive statements regarding ERAS-0015 allegedly lacked a reasonable basis when made.
On April 27, 2026, Erasca disclosed that it had received correspondence from counsel for Revolution Medicines alleging, among other things, patent infringement, trade-secret-related issues, and allegedly improper comparative statements concerning ERAS-0015 and RMC-6236. Later that same day, Erasca disclosed preliminary Phase 1 clinical data regarding ERAS-0015 and reported that one patient who received ERAS-0015 had died after experiencing pneumonitis that progressed following withdrawal of supportive care. The Company also disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses rather than head-to-head clinical trials and that such comparisons were inherently limited. Following these disclosures, Erasca’s share price experienced a substantial decline.
What Can You Do Now? If you are a current Erasca, Inc. (NASDAQ: ERAS) shareholder and have held shares since prior to January 14, 2025, you can seek corporate governance reforms, damages on behalf of the Company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/erasca-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. #Erasca #ERAS $ERAS
Power Solutions International, Inc. (NASDAQ: PSIX):
Grabar Law Office is investigating claims on behalf of shareholders of Power Solutions International, Inc. (NASDAQ: PSIX).
What Is This Investigation About? The investigation concerns whether Power Solutions and certain of its executives breached their fiduciary duties.
If you purchased Power Solutions International, Inc. (NASDAQ: PSIX) shares prior to May 8, 2025, please visit https://grabarlaw.com/the-latest/psix-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever.
What Is Alleged? According to a recently filed federal securities fraud class action complaint, Power Solutions (NASDAQ: PSIX); through certain of its officers, failed to disclose to investors: (1) the Company overstated its ability to capture sales demand for its power systems solutions, particularly within the data center market; (2) the Company understated the impact of its enhancements to manufacturing capacity to meet demand within the data center market, including the expected costs and the nature of the related “inefficiencies”; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What Can You Do Now? If you purchased or otherwise acquired Power Solutions International, Inc. (NASDAQ: PSIX) securities prior to May 8, 2025, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever. Visit https://grabarlaw.com/the-latest/psix-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #PSIX $PSIX #PowerSolutions
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
Media gallery
